Oncología médica

2017

1. A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)

   European Urology Focus, Vol. 3, Núm. 4-5, pp. 430-436

2. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

   Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

3. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

   Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153

4. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

   Journal of the National Cancer Institute, Vol. 109, Núm. 9

5. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

   Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

6. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

   Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1454-1461

7. DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas

   Pathology, Vol. 49, Núm. 7, pp. 731-739

8. Effectiveness and safety of Eribulin in metastatic breast cancer

   European Journal of Clinical Pharmacy, Vol. 19, Núm. 1, pp. 55-59

9. Epithelial ovarian cancer and primary peritoneal carcinomatosis in the elderly: What is our clinical practice?

   European Journal of Gynaecological Oncology, Vol. 38, Núm. 5, pp. 695-699

10. Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study

    PLoS ONE, Vol. 12, Núm. 10

11. Functional proteomics outlines the complexity of breast cancer molecular subtypes

    Scientific Reports, Vol. 7, Núm. 1

12. Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group

    European Journal of Cancer, Vol. 75, pp. 73-82

13. Hereditary pancreatic cancer: Related syndromes and clinical perspective

    Hereditary Cancer in Clinical Practice, Vol. 15, Núm. 1

14. Long-term follow-up of The Intergroup Exemestane Study

    Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2507-2514

15. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700

16. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

    Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421

17. Oncogenic activity of SOX1 in glioblastoma

    Scientific Reports, Vol. 7

18. Predictive and prognostic brain metastases assessment in luminal breast cancer patients: FN14 and GRP94 from diagnosis to prophylaxis

    Frontiers in Oncology, Vol. 7, Núm. DEC

19. Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy

    Journal of Clinical Oncology

20. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

    Stem Cell Reports, Vol. 8, Núm. 5, pp. 1392-1407